Altimmune (ALT) Price & Analysis

Compare

3,622 Followers

ALT Stock Chart & Stats

$3.34

$0.16(2.19%)

At close: Jan 08 4:00 PM EST

$3.34

$0.16(2.19%)

Day’s Range― - ―

52-Week Range$2.90 - $7.73

Previous CloseN/A

Volume1.55M

Average Volume (3M)3.38M

Market Cap

$434.43M

Enterprise Value$286.71M

Total Cash (Recent Filing)$273.46M

Total Debt (Recent Filing)$35.69M

Price to Earnings (P/E)―

Beta1.62

Next Earnings

May 19, 2026

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding130,069,980

10 Day Avg. Volume4,162,091

30 Day Avg. Volume3,378,447

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)1.41

Price to Sales (P/S)7757.46

P/FCF Ratio-4.71

Enterprise Value/Market Cap0.66

Enterprise Value/Revenue6.99K

Enterprise Value/Gross Profit-19.22

Enterprise Value/Ebitda-3.20

Forecast

1Y Price Target

$13.50

Price Target Upside304.19% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-1.12

Revenue Forecast (FY)$6.22K

Bulls Say, Bears Say

Bulls Say

Mechanism Of ActionDual mechanism that suppresses appetite via GLP‑1 activity and directly reduces liver fat via glucagon activity may deliver superior efficacy compared with GLP‑1‑only therapies, increasing the drug's commercial potential.

Regulatory Pathway And Assessment StandardizationRegulatory alignment on key trial parameters combined with use of an FDA‑cleared AI pathology tool could streamline a registrational Phase III program and improve consistency of biopsy-based endpoints.

Tolerability And Patient AdherenceEstablished tolerability with lower discontinuation rates than placebo and a simplified titration dosing plan could improve treatment persistence and broaden trial enrollment, supporting commercial uptake in niche patient groups.

Bears Say

Clinical DifferentiationPhase IIb results showed therapeutic activity but did not demonstrate clear clinical differentiation from competing treatments, which could constrain uptake if superiority is not shown in later trials.

Development And Financing RiskClinical trial, regulatory, and financing risks create substantial uncertainty that could delay development timelines or prevent the drug from reaching the market as anticipated.

Market CompetitionA crowded MASH treatment market with established drugs and emerging competitors raises the need for distinct clinical or commercial advantages, or else market share and pricing could be limited.

Altimmune News

Altimmune initiated with a Buy at Truist

Truist initiated coverage of Altimmune (ALT) with a Buy rating and $12 price target The firm believes that...

5d ago

ALT

Altimmune price target raised to $25 from $12 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Altimmune (ALT) to $25 from $12 and keeps a Buy...

7d ago

ALT

Altimmune price target lowered to $13 from $18 at B. Riley

B. Riley lowered the firm’s price target on Altimmune (ALT) to $13 from $18 and keeps a Buy...

17d ago

ALT

Altimmune reports Q4 EPS (27c), consensus (24c)

Reports Q4 revenue $26,000 vs. $5,000 last year. “In pemvidutide, we have a unique and differentiated compound with...

18d ago

ALT

Options Volatility and Implied Earnings Moves Today, March 05, 2026

Today, several major companies are expected to report earnings: Lineage Therap (LCTX), Ciena (CIEN), Costco (COST), GoPro (GPRO),...

18d ago

ALT

Options Volatility and Implied Earnings Moves This Week, March 02 – March 05, 2026

This week, several major companies will be reporting earnings. Among them are CrowdStrike Holdings (CRWD), Plug Power (PLUG),...

21d ago

Altimmune, Coherent, Globalstar, Bed Bath & Beyond, Linde Insider Shocks

Insiders have been trading these 5 stocks: (($ALT)), (($COHR)), (($GSAT)), (($BBBY)) and (($LIN)). Here is a breakdown of...

9d ago

ALT

LIN

Altimmune Bets Big on PEMB as Phase III Nears

Altimmune (($ALT)) has held its Q4 earnings call. Read on for the main highlights of the call. Altimmune’s...

14d ago

ALT

Is ALT a Buy, Before Earnings?

Altimmune (ALT) is scheduled to report 4th quarter earnings on 03/05/2026, before the market opens. Regarding Q4 estimates,...

20d ago

ALT

Altimmune management to meet with Piper Sandler

Meeting to be held in New York on February 24 hosted by Piper Sandler. Published first on TheFly...

1M ago

ALT

Altimmune initiated with a Buy at Titan Partners

Titan Partners initiated coverage of Altimmune (ALT) with a Buy rating and $7 price target The Phase II...

1M ago

ALT

Short Report: VNET Group short interest at 4-month high

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

1M ago

ALT

APLS

Altimmune Sets 2026 Annual Stockholder Meeting Timeline

Altimmune ( ($ALT) ) has issued an announcement. Altimmune has scheduled its 2026 Annual Meeting of Stockholders for...

2M ago

ALT

Altimmune Announces $75 Million Registered Direct Equity Offering

Altimmune ( ($ALT) ) has shared an announcement. On January 27, 2026, Altimmune, Inc. entered into a Securities...

2M ago

ALT

ALT FAQ

What was Altimmune Inc’s price range in the past 12 months?

Altimmune Inc lowest stock price was $2.90 and its highest was $7.73 in the past 12 months.

What is Altimmune Inc’s market cap?

Altimmune Inc’s market cap is $434.43M.

When is Altimmune Inc’s upcoming earnings report date?

Altimmune Inc’s upcoming earnings report date is May 19, 2026 which is in 57 days.

How were Altimmune Inc’s earnings last quarter?

Altimmune Inc released its earnings results on Mar 05, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.234 by -$0.036.

Is Altimmune Inc overvalued?

According to Wall Street analysts Altimmune Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Altimmune Inc pay dividends?

Altimmune Inc pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here

What is Altimmune Inc’s EPS estimate?

Altimmune Inc’s EPS estimate is -0.24.

How many shares outstanding does Altimmune Inc have?

Altimmune Inc has 130,069,980 shares outstanding.

What happened to Altimmune Inc’s price movement after its last earnings report?

Altimmune Inc reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.234. Following the earnings report the stock price went down -17.916%.

Which hedge fund is a major shareholder of Altimmune Inc?

Currently, no hedge funds are holding shares in ALT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Altimmune Stock Smart Score

Outperform

Fundamentals

Return on Equity

-49.35%

Trailing 12-Months

Asset Growth

100.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune (ALT) Earnings & Revenues

Historic Earnings Reports

ALT Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed a predominantly positive outlook driven by robust Phase II clinical data (early NASH resolution, antifibrotic signals, 7.5% weight loss at 48 weeks), favorable tolerability, FDA Breakthrough designation, clear alignment with the FDA on Phase III design, completed AUD enrollment, and a strengthened balance sheet with a pro forma cash position (~$340M) providing runway into 2028. Key risks discussed included increased near-term operating expenses and G&A, a widened net loss, reliance on biopsy-driven endpoints (NITs not yet registrational), operational and enrollment execution risks for a large global Phase III, and competitive dynamics in the dual-agonist space. On balance, the positives (clinical differentiation, regulatory progress, funding runway, commercial interest) outweigh the challenges, though execution and funding discipline will be critical as Phase III is initiated.View all ALT earnings summaries

ALT Stock 12 Month Forecast

Average Price Target

$13.50

▲(304.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","8":"$8","14":"$14","20":"$20","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.01,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8,14,20,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.16,5.763076923076923,7.366153846153846,8.96923076923077,10.572307692307692,12.175384615384615,13.778461538461539,15.381538461538462,16.984615384615385,18.587692307692308,20.19076923076923,21.793846153846154,23.396923076923077,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.16,4.878461538461538,5.596923076923077,6.315384615384616,7.033846153846154,7.752307692307692,8.470769230769232,9.18923076923077,9.907692307692308,10.626153846153846,11.344615384615384,12.063076923076924,12.781538461538462,{"y":13.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.16,4.148461538461539,4.136923076923077,4.125384615384616,4.113846153846154,4.102307692307693,4.090769230769231,4.079230769230769,4.067692307692307,4.056153846153846,4.044615384615384,4.033076923076923,4.021538461538461,{"y":4.01,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.745,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 55, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >